United Therapeutics Corporation UTHR reported fourth quarter earnings of $3.68 per share (excluding stock-based compensation expense), up 30% from the year-ago period. The Zacks Consensus Estimate for fourth quarter 20Array5 earnings was $2.57 per share. Including stock-based compensation expense, earnings were $2.2Array per share.
Revenues for the reported quarter increased Array7% year over year to $404.9 million, surpassing the Zacks Consensus Estimate of $377 million.
Full year revenues increased Array4% to $Array.47 billion while earnings jumped 33.2% to $Array2.33 per share.
The Quarter in Detail
Revenues in the fourth quarter grew from the year-ago period due to an increase in the number of patients being treated with Orenitram and higher Adcirca revenues as well as Unituxin sales.
Orenitram, which was launched in 20Array4, registered sales of $37.3 million in the third quarter of 20Array5, up 85% from the year-ago period and 8.4% sequentially.
On the call, the company said that Orenitram revenues were driven by new patient starts, which were Array4% higher than in the third quarter of 20Array5 reflecting a growing number of prescribers. About 70% of the patient starts in the fourth quarter were from patients new to prostacyclin. However, the balance represented transitions from Tyvaso or Remodulin.
Increasing patient referrals in the fourth quarter should boost Orenitram sales in the first quarter of 20Array6.
Remodulin revenues grew 3% from the year-ago quarter to $Array40.5 million. Meanwhile, Tyvaso and Adcirca contributed $ArrayArray9.Array million (up 4%) and $9Array.6 million (up 25%), respectively, to fourth-quarter revenues. Recently launched Unituxin delivered revenues of $Array5.7 million, up from $4.7 million in the third quarter.
Research and development (R&D) expenses for the fourth quarter grew 6% from the year-ago quarter to $75.9 million mainly due to higher share-based compensation expense.
Selling, general and administrative (SG&A) expenses shot up 84% from the year-ago quarter, also due to higher share-based compensation expense.
Meanwhile, the company is looking to bring its lead product, Remodulin, in the form of an implantable pump system to markets. The company has a collaboration agreement with Medtronic MDT for the development of an implantable pump (the SynchroMed II implantable drug infusion system) to deliver Remodulin.
Our Take
United Therapeutics’ fourth quarter revenues were strong, comfortably surpassing expectations. While Orenitram sales should continue picking up on the back of new patient starts, increasing patient referrals, continued transition from other treatments including Tyvaso and Remodulin and increasing uptake in community centers, Actelion’s ALIOF recently launched Uptravi could have a near-term impact on sales. We expect investor focus to remain on Orenitram sales ramp and pipeline updates.
United Therapeutics is a Zacks Rank #3 (Hold) stock. A better-ranked stock in the health care sector is Gilead Sciences Inc. GILD, a Zacks Rank #Array (Strong Buy) stock.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment